Stockscreener 앱 받기
4.27
4.26%
-0.19
시간 외 거래:
4.24
-0.03
-0.70%
전일 마감가:
$4.46
열려 있는:
$4.47
하루 거래량:
173.16K
Relative Volume:
0.56
시가총액:
$180.55M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-14.43%
1개월 성능:
-5.74%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.20
$4.47
1주일 범위
$4.20
$5.025
52주 변동 폭
$2.92
$7.20
Tuhura Biosciences Inc Stock (HURA) Company Profile
명칭
Tuhura Biosciences Inc
전화
813-875-6600
주소
10500 UNIVERSITY CENTER DR., TAMPA
HURA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
4.27 | 180.55M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 개시 | Rodman & Renshaw | Buy |
| 2024-11-05 | 개시 | Maxim Group | Buy |
Tuhura Biosciences Inc 주식(HURA)의 최신 뉴스
Research Analysts Issue Forecasts for HURA Q2 Earnings - Defense World
TuHURA Biosciences’ Acquisition of Kineta - Global Legal Chronicle
Q2 Earnings Forecast for HURA Issued By Zacks Small Cap - MarketBeat
TuHURA Biosciences (HURA) Expected to Announce Earnings on Wednesday - MarketBeat
TuHURA Biosciences (HURA) Projected to Post Quarterly Earnings on Wednesday - Defense World
TuHURA Biosciences (NASDAQ:HURA) Stock Price Down 2.6%Here's Why - MarketBeat
TuHURA Biosciences (NASDAQ:HURA) Trading Down 2.6% – Here’s What Happened - Defense World
When Will TuHURA Biosciences, Inc. (NASDAQ:HURA) Turn A Profit? - Simply Wall St
When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)? - Yahoo Finance
Analyzing Enveric Biosciences (NASDAQ:ENVB) and TuHURA Biosciences (NASDAQ:HURA) - Defense World
Rep. Laurel M. Lee Purchases Shares of TuHURA Biosciences (NASDAQ:HURA) - Defense World
Rep. Laurel M. Lee Buys TuHURA Biosciences (NASDAQ:HURA) Shares - MarketBeat
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc.HURA - The Eastern Progress Online
TuHURA Biosciences appoints new accounting firm By Investing.com - Investing.com Australia
TuHURA Biosciences appoints new accounting firm - Investing.com India
TuHURA Biosciences (NASDAQ:HURA) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders - Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders - Finansavisen
H.C. Wainwright sets $11 target on HURA with buy rating - Investing.com
Cancer Immunotherapy: TuHURA Biosciences to Acquire Kineta - orrick.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, ML, HURA, KANT on Behalf of Shareholders - Finansavisen
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, HURA, KANT on Behalf of Shareholders - GlobeNewswire
TuHURA Biosciences, Inc. entered into a non-binding agreement to acquire Kineta, Inc. from Craig Philips and others for $30 million. - Marketscreener.com
TuHURA Biosciences to Acquire Kineta - citybiz
HURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of TuHURA Biosciences, Inc. Is Fair to Shareholders - The Bakersfield Californian
TuHURA Biosciences to Acquire Kineta, Inc. in 2025 - TipRanks
Kineta Merges with TuHURA to Enhance Cancer Treatment - TipRanks
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. - Sacramento Bee
TuHURA to acquire Kineta in immunotherapy push - Investing.com
TuHURA to acquire Kineta in immunotherapy push By Investing.com - Investing.com UK
TuHURA Biosciences to Acquire Kineta, Adding Promising Phase 2 Cancer Immunotherapy to Pipeline - StockTitan
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024 - The Eastern Progress Online
Stock market today: Unusual Machines +95.34%, VCI Global Limited +52.23% among top gainers in early trading - Business Upturn
TuHURA gears up for Phase 3 cancer trial in 2025 By Investing.com - Investing.com South Africa
Kineta and TuHURA Enter Acquisition Agreement - TipRanks
TuHURA Biosciences Advances in Cancer Immunotherapy Innovations - TipRanks
TuHURA gears up for Phase 3 cancer trial in 2025 - Investing.com
TuHURA Biosciences expects to complete enrollment for REM-001 study in Q4 - TipRanks
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell... - Markets Insider
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update - Eagle-Tribune
Rep. Laurel M. Lee TuHURA Biosciences (NASDAQ:HURA) Stock - Defense World
Rep. Laurel M. Lee TuHURA Biosciences (NASDAQ:HURA) Shares - MarketBeat
TuHURA Biosciences Announces Executive Salary and Stock Options - TipRanks
TuHURA Biosciences Inc (HURA) Quarterly 10-Q Report - Quartz
TuHURA Biosciences Inc expected to post a loss of 10 cents a shareEarnings Preview - XM
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - AccessWire
Tuhura Biosciences Inc (HURA) 재무 분석
Tuhura Biosciences Inc (HURA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.03%
자본화:
|
볼륨(24시간):